BCAB (BioAtla) Research & Development: $35.80 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BCAB BioAtla Inc BCAB
15 GF Score
Price $3.30
! 3 Warning Signs
View Full Analysis

What is BioAtla Research & Development?

BioAtla BCAB -2.66% 15 Research & Development is $35.80 Mil as of Mar. 2026. GuruFocus rates BCAB with a GF Score™ of 15/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. BioAtla's Research & Development for the three months ended in Mar. 2026 was $4.58 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $35.80 Mil.

BioAtla  (NAS:BCAB) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

BioAtla Research & Development Related Terms

BioAtla Research & Development Historical Data

* Premium members only.

The historical data trend for BioAtla's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioAtla Research & Development Chart

BioAtla Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 58.27 79.35 103.73 63.10 43.57

BioAtla Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.36 13.68 9.54 8.00 4.58
BCAB
15GF Score
BioAtla Inc BCAB
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioAtla Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $35.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $35.80 Mil mean?
BioAtla (BCAB) has a Research & Development of $35.80 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on BioAtla and its competitors.
Is BioAtla's Research & Development too high?
BioAtla's current Research & Development is $35.80 Mil. Overall, BioAtla has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does BioAtla's Research & Development compare to RNAZ and APVO?
BioAtla's Research & Development of $35.80 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on BioAtla and its competitors. BioAtla's current Research & Development is $35.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioAtla stock overvalued right now?
BioAtla (BCAB) has a current Research & Development of $35.80 Mil. The current Research & Development is $35.80 Mil. BioAtla's overall GF Score™ is 15/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For BioAtla (BCAB), the current Research & Development is $35.80 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioAtla Business Description

Address 11085 Torreyana Road, San Diego, CA, USA, 92121
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.
15GF Score

Get the complete analysis for BCAB

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.30
Price